Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer

Laura M. Spring; Hyo Han; Minetta C. Liu; Erika Hamilton; Hanna Irie; Cesar A. Santa-Maria; James Reeves; Peng Pan; Ming Shan; Yongqiang Tang; Julie R. Graham; Sebastien Hazard; Leif W. Ellisen; Steven J. Isakoff

doi:10.1038/s43018-022-00400-2

Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer

Laura M. Spring
, Hyo Han
, Minetta C. Liu
, Erika Hamilton
, Hanna Irie
, Cesar A. Santa-Maria
, James Reeves
, Peng Pan
, Ming Shan
, Yongqiang Tang
, Julie R. Graham
, Sebastien Hazard
, Leif W. Ellisen
, Steven J. Isakoff

School of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

This single-arm pilot study (NCT03329937) evaluated neoadjuvant niraparib antitumor activity and safety in patients with localized HER2-negative, BRCA-mutated breast cancer. Twenty-one patients received niraparib 200 mg once daily in 28-day cycles. After 2 cycles, tumor response (≥30% reduction from baseline) by MRI was 90.5% and 40.0% (6 of 15) of patients who received only niraparib (2–6 cycles) had pathological complete response; no new safety signals were identified. High niraparib intratumoral concentration was observed.

Original language	English (US)
Pages (from-to)	927-931
Number of pages	5
Journal	Nature Cancer
Volume	3
Issue number	8
DOIs	https://doi.org/10.1038/s43018-022-00400-2
State	Published - Aug 2022

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1038/s43018-022-00400-2

Cite this

@article{0af9dbc21b2d46578d435e48030d7317,

title = "Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer",

abstract = "This single-arm pilot study (NCT03329937) evaluated neoadjuvant niraparib antitumor activity and safety in patients with localized HER2-negative, BRCA-mutated breast cancer. Twenty-one patients received niraparib 200 mg once daily in 28-day cycles. After 2 cycles, tumor response (≥30\% reduction from baseline) by MRI was 90.5\% and 40.0\% (6 of 15) of patients who received only niraparib (2–6 cycles) had pathological complete response; no new safety signals were identified. High niraparib intratumoral concentration was observed.",

author = "Spring, \{Laura M.\} and Hyo Han and Liu, \{Minetta C.\} and Erika Hamilton and Hanna Irie and Santa-Maria, \{Cesar A.\} and James Reeves and Peng Pan and Ming Shan and Yongqiang Tang and Graham, \{Julie R.\} and Sebastien Hazard and Ellisen, \{Leif W.\} and Isakoff, \{Steven J.\}",

note = "Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

month = aug,

doi = "10.1038/s43018-022-00400-2",

language = "English (US)",

volume = "3",

pages = "927--931",

journal = "Nature Cancer",

issn = "2662-1347",

publisher = "Nature Research",

number = "8",

}

TY - JOUR

T1 - Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer

AU - Spring, Laura M.

AU - Han, Hyo

AU - Liu, Minetta C.

AU - Hamilton, Erika

AU - Irie, Hanna

AU - Santa-Maria, Cesar A.

AU - Reeves, James

AU - Pan, Peng

AU - Shan, Ming

AU - Tang, Yongqiang

AU - Graham, Julie R.

AU - Hazard, Sebastien

AU - Ellisen, Leif W.

AU - Isakoff, Steven J.

PY - 2022/8

Y1 - 2022/8

N2 - This single-arm pilot study (NCT03329937) evaluated neoadjuvant niraparib antitumor activity and safety in patients with localized HER2-negative, BRCA-mutated breast cancer. Twenty-one patients received niraparib 200 mg once daily in 28-day cycles. After 2 cycles, tumor response (≥30% reduction from baseline) by MRI was 90.5% and 40.0% (6 of 15) of patients who received only niraparib (2–6 cycles) had pathological complete response; no new safety signals were identified. High niraparib intratumoral concentration was observed.

AB - This single-arm pilot study (NCT03329937) evaluated neoadjuvant niraparib antitumor activity and safety in patients with localized HER2-negative, BRCA-mutated breast cancer. Twenty-one patients received niraparib 200 mg once daily in 28-day cycles. After 2 cycles, tumor response (≥30% reduction from baseline) by MRI was 90.5% and 40.0% (6 of 15) of patients who received only niraparib (2–6 cycles) had pathological complete response; no new safety signals were identified. High niraparib intratumoral concentration was observed.

UR - https://www.scopus.com/pages/publications/85133364710

UR - https://www.scopus.com/pages/publications/85133364710#tab=citedBy

U2 - 10.1038/s43018-022-00400-2

DO - 10.1038/s43018-022-00400-2

M3 - Article

C2 - 35788722

AN - SCOPUS:85133364710

SN - 2662-1347

VL - 3

SP - 927

EP - 931

JO - Nature Cancer

JF - Nature Cancer

IS - 8

ER -

Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this